GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » PensionAndRetirementBenefit

Zenith Capital (Zenith Capital) PensionAndRetirementBenefit : $0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital PensionAndRetirementBenefit?

Zenith Capital's PensionAndRetirementBenefit for the quarter that ended in . 20 was $0.00 Mil.


Zenith Capital PensionAndRetirementBenefit Historical Data

The historical data trend for Zenith Capital's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital PensionAndRetirementBenefit Chart

Zenith Capital Annual Data
Trend
PensionAndRetirementBenefit

Zenith Capital Quarterly Data
PensionAndRetirementBenefit

Zenith Capital PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines